The best thing investors can take from these types of reports is the information provided to us about the target market we are entering.
It gives us an understanding of what the two majors have paid and what they have compared to what admedus is making.
There are clear differences and clear advantages
News: AHZ Admedus Says Cardiocel 3D And Vascucel Receives European Regulatory Approval, page-407
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.00 |
Change
0.035(0.19%) |
Mkt cap ! $346.0M | |||
| Open | High | Low | Value | Volume |
| $18.00 | $18.00 | $17.65 | $75.19K | 4.184K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 414 | $17.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.10 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |